For example, epidermal growth factor (EGFR) mutations (21) and anaplastic lymphoma kinase (ALK) rearrangements (22) were identified as independent prognostic factors for advanced NSCLC, thus, EGFR tyrosine kinase inhibitors (23) and ALK inhibitors (24) were developed to target these two genes, and proved successful in the treatment of advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.